A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Tibulizumab (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 May 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Planned End Date changed from 13 Mar 2019 to 12 Apr 2019.
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.